Supreme Court to Rule on 'Skinny Labeling' in Generic Drug Case: Impact on Medicine Access

The U.S. Supreme Court is set to hear oral arguments on Wednesday in a case that could reshape the landscape of generic drug access in the United States. The controversy centers on a tactic known as skinny labeling, a strategy employed by generic drug manufacturers to navigate patent laws while bringing lower-cost alternatives to market.

The session has drawn widespread attention due to its potential implications for the availability, pricing, and competition of generic medicines—a critical issue for healthcare consumers and policymakers alike.

What Is Skinny Labeling?

Skinny labeling refers to the practice where generic drug companies seek regulatory approval to market a medication for a specific, non-patented use—even if the brand-name version is prescribed for multiple uses. For example, a generic drug might be approved to treat one type of heart condition but not another, even if the brand-name drug is prescribed for both.

By doing so, generic manufacturers aim to avoid patent infringement lawsuits that could delay or block their entry into the market. This strategy has been a cornerstone of generic drug competition since the Hatch-Waxman Act was enacted over 40 years ago.

The Hatch-Waxman Act and Its Role in Generic Drug Competition

The Hatch-Waxman Act, signed into law in 1984, established the regulatory framework that allows generic drugs to enter the market more efficiently. One of its key provisions was the creation of the Abbreviated New Drug Application (ANDA) pathway, which enables generic manufacturers to demonstrate bioequivalence to a brand-name drug without repeating costly clinical trials.

The law also introduced the concept of carve-outs, where generic drugs could be approved for a subset of the brand-name drug’s approved uses. This tactic—commonly referred to as skinny labeling—was intended to foster competition, lower drug prices, and expand patient access to affordable medications.

Why This Supreme Court Case Matters

The case before the Supreme Court involves a dispute between GSK (GlaxoSmithKline) and Teva Pharmaceuticals. GSK, the manufacturer of the brand-name drug Coreg (carvedilol), sued Teva for patent infringement after Teva sought approval to market a generic version of Coreg under a skinny label, limiting its use to heart failure and not high blood pressure—a use still protected by GSK’s patents.

The lower courts have issued conflicting rulings on the matter. In 2020, a federal jury found Teva liable for inducing patent infringement by encouraging doctors and patients to use the generic version for unapproved purposes. However, the U.S. Court of Appeals for the Federal Circuit later overturned that decision, ruling that Teva’s skinny label did not constitute inducement.

Legal experts and industry stakeholders are closely monitoring the Supreme Court’s decision, as it could set a precedent that either strengthens or weakens the ability of generic manufacturers to use skinny labeling as a competitive tool.

Potential Implications for Patients and the Healthcare System

A ruling against Teva could discourage generic manufacturers from pursuing skinny labeling strategies, potentially reducing competition and keeping drug prices higher for consumers. Conversely, a decision in favor of Teva could reinforce the use of carve-outs, leading to more generic drug approvals and greater savings for patients.

The outcome may also influence how pharmaceutical companies approach patent strategies, litigation, and market exclusivity for brand-name drugs.